tiprankstipranks
Advertisement
Advertisement
Edwards Lifesciences Buy Rating Reaffirmed as Favorable TAVR Policy Update Supports Growth and $100 Price Target Maintained
PremiumRatingsEdwards Lifesciences Buy Rating Reaffirmed as Favorable TAVR Policy Update Supports Growth and $100 Price Target Maintained
5d ago
Edwards Lifesciences’ HPI Care Trial Posts Results, Offering Fresh Signals for Predictive Monitoring Investors
Premium
Company Announcements
Edwards Lifesciences’ HPI Care Trial Posts Results, Offering Fresh Signals for Predictive Monitoring Investors
11d ago
Analyst Initiates Buy on Edwards Lifesciences, Citing Favorable TAVR Reimbursement Outlook and Expanded Patient Access Potential
Premium
Ratings
Analyst Initiates Buy on Edwards Lifesciences, Citing Favorable TAVR Reimbursement Outlook and Expanded Patient Access Potential
13d ago
Edwards Lifesciences Maintained at Buy as Strong Q1 Results and RESILIA Durability Data Support Elevated 2026 Outlook and Unchanged $97 Price Target
PremiumRatingsEdwards Lifesciences Maintained at Buy as Strong Q1 Results and RESILIA Durability Data Support Elevated 2026 Outlook and Unchanged $97 Price Target
2M ago
Edwards Lifesciences announces 10-year results from Commence aortic trial
Premium
The Fly
Edwards Lifesciences announces 10-year results from Commence aortic trial
2M ago
Edwards Lifesciences price target raised to $110 from $104 at Barclays
Premium
The Fly
Edwards Lifesciences price target raised to $110 from $104 at Barclays
2M ago
Edwards Lifesciences price target raised to $87 from $85 at Baird
PremiumThe FlyEdwards Lifesciences price target raised to $87 from $85 at Baird
2M ago
Edwards Lifesciences price target lowered to $100 from $103 at BofA
Premium
The Fly
Edwards Lifesciences price target lowered to $100 from $103 at BofA
2M ago
Closing Bell Movers: Intel jumps 19% on blowout earnings
Premium
The Fly
Closing Bell Movers: Intel jumps 19% on blowout earnings
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100